Pascoe shed some insight into the company's strategy during the recent Stifel conference presentation...
When he spoke of Vitaros US, he had a very compelling explanation as to why he thinks V-US could get through an NDA now (next year), and spoke to the issues as to why it failed to get approved the first time. Sci101 on the other board had a very insightful explanation of the matter a couple weeks back, that Pascoe appeared to confirm in his presentation...related to studies with transgenic mice.
Pascoe also seemed to favor Allergan becoming the company to market V-US. That means the company would favor the $25M one time "opt in" buy back rights to market V, as well as the high double digit royalties that that deal involves. Question: Does that mean high teens or some other high double digit? I find it very interesting that Pascoe also noted that Allergan and Pfizer (though he didn't name Pfizer specifically) are involved in the news recently...referring to merger talks I assume. Topical Viagra? :) If Allergen failed to opt in, Pascoe mentioned the strategy would be to find another company to market V, or market the product directly...he did not seem convincing when he spoke of the later route.
So what's that all mean to me? Pascoe wants the $25M to help develop Fispemifine, which is why Denner (Sarissa) is here...one could presume. Clearly there is remarkable potential for Fis. Of course, secondary hypogonadism and that market (a potential $1B in the US) will be the target for getting Fis through the NDA, but Prostatis and Luts markets are staggering as well.
Vitaros worldwide sales alone can make this company successful...and give us a return on our investment, in my opinion. Especially, with the US back in play. If they can pull off Fispemifine, or at least retain a significant interest in it, the results could be staggering.
This stock is painful to own, yet I can not help but think that good times are ahead. This company is doing too many things right.
My 2 cents worth...or $1.20 worth :) |
